Measurement of CD44 expression indicated that in 80% of tumors, CD49f+CD24+(PP) cell populations were greater than 75% CD44 positive (51-99%, Figure 2A); in contrast, CD49f+CD24−(PM), CD49f−CD24+(MP), and CD49f−CD24−(MM) cell populations exhibited a range of CD44 expression: PM (range: 11-84%), MP (range: 20-92%), and MM (range: 11-84%). This evidence concerns the gene ITGA6 and Miyoshi myopathy.